Logo image of ARGX

ARGENX SE - ADR (ARGX) Stock Price, Quote, News and Overview

NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR - Currency: USD

542.47  -18.43 (-3.29%)

After market: 542.47 0 (0%)

ARGX Quote, Performance and Key Statistics

ARGENX SE - ADR

NASDAQ:ARGX (5/13/2025, 4:05:09 PM)

After market: 542.47 0 (0%)

542.47

-18.43 (-3.29%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High678.21
52 Week Low356.38
Market Cap33.12B
Shares61.06M
Float60.98M
Yearly DividendN/A
Dividend YieldN/A
PE92.41
Fwd PE24.33
Earnings (Next)07-31 2025-07-31/bmo
IPO07-10 2014-07-10


ARGX short term performance overview.The bars show the price performance of ARGX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10

ARGX long term performance overview.The bars show the price performance of ARGX in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80

The current stock price of ARGX is 542.47 USD. In the past month the price decreased by -3.45%. In the past year, price increased by 53.33%.

ARGENX SE - ADR / ARGX Daily stock chart

ARGX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.31 332.57B
AMGN AMGEN INC 13.03 145.41B
GILD GILEAD SCIENCES INC 13.1 126.28B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.06B
REGN REGENERON PHARMACEUTICALS 12.96 61.99B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.71B
ONC BEIGENE LTD-ADR 5.58 24.22B
BNTX BIONTECH SE-ADR N/A 22.72B
NTRA NATERA INC N/A 20.70B
SMMT SUMMIT THERAPEUTICS INC N/A 18.30B
BIIB BIOGEN INC 7.79 18.05B
UTHR UNITED THERAPEUTICS CORP 12.29 13.90B

About ARGX

Company Profile

ARGX logo image argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

Company Info

ARGENX SE - ADR

Laarderhoogtweg 25

Amsterdam NOORD-HOLLAND 4811 AH NL

CEO: Tim Van Hauwermeiren

Employees: 1599

ARGX Company Website

ARGX Investor Relations

Phone: 31763030

ARGENX SE - ADR / ARGX FAQ

What is the stock price of ARGENX SE - ADR today?

The current stock price of ARGX is 542.47 USD. The price decreased by -3.29% in the last trading session.


What is the ticker symbol for ARGENX SE - ADR stock?

The exchange symbol of ARGENX SE - ADR is ARGX and it is listed on the Nasdaq exchange.


On which exchange is ARGX stock listed?

ARGX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARGENX SE - ADR stock?

26 analysts have analysed ARGX and the average price target is 792.74 USD. This implies a price increase of 46.14% is expected in the next year compared to the current price of 542.47. Check the ARGENX SE - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARGENX SE - ADR worth?

ARGENX SE - ADR (ARGX) has a market capitalization of 33.12B USD. This makes ARGX a Large Cap stock.


How many employees does ARGENX SE - ADR have?

ARGENX SE - ADR (ARGX) currently has 1599 employees.


What are the support and resistance levels for ARGENX SE - ADR (ARGX) stock?

ARGENX SE - ADR (ARGX) has a support level at 553.8 and a resistance level at 638.33. Check the full technical report for a detailed analysis of ARGX support and resistance levels.


Is ARGENX SE - ADR (ARGX) expected to grow?

The Revenue of ARGENX SE - ADR (ARGX) is expected to grow by 64.81% in the next year. Check the estimates tab for more information on the ARGX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ARGENX SE - ADR (ARGX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARGENX SE - ADR (ARGX) stock pay dividends?

ARGX does not pay a dividend.


When does ARGENX SE - ADR (ARGX) report earnings?

ARGENX SE - ADR (ARGX) will report earnings on 2025-07-31, before the market open.


What is the Price/Earnings (PE) ratio of ARGENX SE - ADR (ARGX)?

The PE ratio for ARGENX SE - ADR (ARGX) is 92.41. This is based on the reported non-GAAP earnings per share of 5.87 and the current share price of 542.47 USD. Check the full fundamental report for a full analysis of the valuation metrics for ARGX.


What is the Short Interest ratio of ARGENX SE - ADR (ARGX) stock?

The outstanding short interest for ARGENX SE - ADR (ARGX) is 3.75% of its float. Check the ownership tab for more information on the ARGX short interest.


ARGX Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ARGX. When comparing the yearly performance of all stocks, ARGX is one of the better performing stocks in the market, outperforming 91.39% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ARGX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ARGX. While ARGX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARGX Financial Highlights

Over the last trailing twelve months ARGX reported a non-GAAP Earnings per Share(EPS) of 5.87. The EPS increased by 194.52% compared to the year before.


Industry RankSector Rank
PM (TTM) 37.99%
ROA 13.41%
ROE 15.13%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%348.08%
Sales Q2Q%95.72%
EPS 1Y (TTM)194.52%
Revenue 1Y (TTM)78.63%

ARGX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to ARGX. The Buy consensus is the average rating of analysts ratings from 26 analysts.

For the next year, analysts expect an EPS growth of 576.65% and a revenue growth 64.81% for ARGX


Ownership
Inst Owners39.35%
Ins Owners0.12%
Short Float %3.75%
Short Ratio5.47
Analysts
Analysts84.62
Price Target792.74 (46.14%)
EPS Next Y576.65%
Revenue Next Year64.81%